Patrick J. Haley, Executive Vice President, Commercial at EXELIXIS, INC., executed a sale of 32,110 shares of the company's common stock on May 20, 2026.
The proceeds from this divestiture totaled $1,599,399. The pricing for these sold shares ranged between $49.80 and $49.89. Notably, this transaction took place while the company's stock was trading near its 52-week high of $51.63, with the current market price recorded at $50.15.
Following the sale, Mr. Haley maintains a direct holding of 357,638 shares of EXELIXIS common stock. This total ownership stake comprises 356,992 shares that are scheduled for issuance upon the vesting of restricted stock units (RSUs) and performance-based restricted stock unit awards.
Financial Performance and Strategic Developments
The biotech firm, which has a market valuation of $12.61 billion, appears to be trading below its perceived fair value, according to an InvestingPro analysis. This assessment suggests the stock is currently undervalued relative to expert projections. Further detailed insights into this matter are available through a comprehensive Pro Research Report that covers EXEL and over 1,400 other US equities, providing key metrics alongside expert analysis.
In separate but relevant corporate news, Exelixis Inc. reported robust financial results for the first quarter of 2026. These results surpassed expectations across both revenue and earnings measures. Specifically, the company posted an Earnings Per Share (EPS) of $0.87 per share. This figure exceeded the anticipated level of $0.77, marking a surprise increase of 12.99%. Furthermore, revenues also outperformed forecasts, reaching $611 million when analysts had projected $608.95 million.
Beyond its strong quarterly financials, Exelixis announced a significant clinical development collaboration with Merck. This partnership focuses on advancing a Phase 3 trial for patients diagnosed with resected stage II/III colorectal cancer. Under the terms of this agreement, Exelixis will be responsible for sponsoring the pivotal STELLAR-316 trial. Concurrently, Merck has agreed to contribute its subcutaneous anti-PD-1 therapy, known as KEYTRUDA QLEX.
Analysis and Market Context
These recent developments collectively underscore Exelixis's sustained efforts to advance both its clinical pipeline and its financial objectives. The reported sales activity by a top executive occurs alongside this positive operational news, providing mixed signals regarding internal confidence in the stock price.
The company's stock data shows various trading metrics: at one point, it was listed at $50.15 (a gain of +0.50 or +1.01% on the day). After-hours trading saw a different movement, reaching $51.10 (a gain of +0.95 or +1.89%). The stock chart also provides historical context, showing price movements across various time frames from 1 day to 5 years.
Key Takeaways and Sector Impact
- Execution Risk in Clinical Trials: The success of the pivotal STELLAR-316 trial and the overall clinical development collaboration with Merck are contingent upon positive patient outcomes and regulatory approval.
- Market Sentiment Divergence: The executive selling activity, juxtaposed against strong financial results and strategic partnerships, introduces uncertainty regarding internal perception versus external market valuation.